Abstract 4436
Background
Trastuzumab (T) + chemo is standard 1st line therapy (tx) for HER2+ GEA patients (pts). Pts typically progress in 6-8 months, with loss of HER2 positivity in 40% of treated pts. No anti-HER2 agents are approved in the post-T setting. We report the results of M, an anti-HER2 monoclonal antibody Fc-optimized for antibody-dependent cellular cytotoxicity, + P in HER2+ GEA pts and describe potential strategies for biomarker-guided response enrichment based on ERBB2 amplification and/or PD-L1 expression.
Methods
HER2+, PD-L1-unselected, 2nd line GEA pts post T progression received M (15 mg/kg Q3) + P (200 mg Q3). Safety, objective response rate (ORR), median overall and progression-free survival (mOS, mPFS), disease control rate (DCR), circulating-tumor DNA (ctDNA), and tumor PD-L1 expression were assessed.
Results
At data cutoff, 60 GEA pts were dosed in cohort expansion; 16.7% had treatment-related adverse events ≥ Grade 3. Overall, 21.6% had objective response (OR), 10 confirmed and 3 unconfirmed. DCR was 55% and mOS was 15.6 mos (95% CI: 7.26, NR). In GC pts, OR occurred in 10 of 34 (29.4%), mPFS was 4.24 mos (95% CI: 1.68, 5.62), and mOS not reached. Notably, only 31 of 51 (61%) of pts with baseline ctDNA testing showed ERBB2-amplification; 21 of 30 (70%) of pts with fresh tumor biopsy were HER2 3+ by IHC (80% concordance). Tumors were PD-L1+ positive in 13 of 28 (46%) pts tested, with higher rates in pts with GC. The presence of ERBB2 amplification by ctDNA and tumor PD-L1 expression by IHC were both associated with increased probability of OR: 33.3% v. 10.5% (p = 0.0948) and 43.8% v. 16.7% (p = 0.0769), respectively. ORR was 5 of 8 (62.5%) in ERBB2 amplified/PD-L1+ pts. In pts with activating HER2 mutations DCR was 11/15 (73%), indicating ADCC.
Conclusions
Consistent with prior tissue-based reports, many GEA pts progressing on T have lost ERBB2 amp. ERBB2 status by ctDNA NGS post-T could help identify patients more likely to respond to M+P, particularly in PD-L1+ pts. Our results suggest that M+P is well tolerated and has encouraging preliminary activity in 2nd line HER2+ GEA. Biomarker selection may further enrich for responding pts, advancing a potential chemo-free regimen in this population.
Clinical trial identification
NCT02689284.
Legal entity responsible for the study
MacroGenics, Inc.
Funding
MacroGenics, Inc.
Editorial Acknowledgement
Not Applicable
Disclosure
D.V.T. Catenacci: Honoraria: Merck, BMS, Lilly, Genentech/Roche, Amgen, Taiho, Guardant Health, Foundation Medicine; Research funding: Genentech/Roche. H.E. Uronis: Consulting, Advisory role: Bristol-Myers Squibb; Research funding: Genentech/Roche, Bristol-Myers Squibb, Advaxis, MacroGenics, Merck. Y-K. Kang: Consulting, Advisory role: Lily/ImClone, Taiho Pharmaceutical, Ono Pharmaceutical, Roche/Genentech, Novartis; Research funding: LSK Biopharma. M. Ng: Consulting, Advisory role: MSD Oncology, Bristol-Myers Squibb; Honoraria: Taiho Pharmaceutical; Research funding: ASLAN Pharmaceuticals. J. Lacy: Advisory board: Celgene. P.C. Enzinger: Consultant: Astellis, Celgene, FivePrime, Lilly, Loxo, Merck, Taiho. K-W. Lee: Research funding: AstraZeneca/Medimmune, Green Cross Corp, MSD, Ono Pharmaceutical, Merck KGaA, Five Prime Therapeutics, MacroGenics, ASLAN Pharmaceuticals, LSK BioPharma, Array BioPharma, Pharmacyclics, Pfizer. J. Yen, A. Franovic: Employee: Guardant Health. J. Odegaard: Employee, Stock holder: Guardant Health. J. Baughman: Employee: MacroGenics, Inc. J. Muth, T. Wu, A. Wynter-Horton: Employee, Stock ownership: MacroGenics, Inc. J. Wigginton, J.K. Davidson-Moncada: Employee, Leadership, Stock and other ownership interests: MacroGenics. Y-J. Bang: Consulting, Advisory role: Samyang; Research funding: AstraZeneca/Medimmune, Novartis, Genentech/Roche, MSD, Merck/Serano, Bayer, GlaxoxSmithKline, Bristol-Myers Squibb, Pfizer, Lilly, Boehringer Ingelheim, MacroGenics, Boston Miomedical, kFive Prime Therapeutics, Chong Kun Dang Pharmaceutical, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda, BeiGene, Curis, Green Cross Corp. All other authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract